Kooij Louise Frederika, the Chief Accounting Officer of NewAmsterdam Pharma (NAMS), has been a consistent seller of company stock over the past year, with Form 4 filings showing 39 total transactions worth $21.28 million in sales and zero open-market purchases. The most recent activity, dated July 20, 2026, shows three separate sales totaling roughly $3.19 million, paired with two option exercises valued at $1.19 million—a pattern that suggests the sales are tied to the conversion of equity compensation rather than discretionary divestment. This same structure repeats across the filing history: on June 22, 2026, she sold approximately $1.21 million while exercising options worth $451,000, and on May 26, 2026, she sold $2.32 million against $654,500 in option exercises.
The selling cadence has been steady but not frantic, with transactions clustered around monthly intervals from January through July 2026. January was the heaviest month, featuring sales on five separate days totaling roughly $4.74 million, accompanied by option exercises and a zero-value grant award on January 7. The largest single sale came on May 26 at $2.32 million, while the smallest was a $9,219 disposition on June 22. All transactions involved NAMS shares exclusively, and the absence of any code "P" purchases—the only transaction type that signals conviction buying—underscores a one-directional bias toward liquidity. The option exercises (code "M") and tax-withholding sales (code "F") are mechanical by nature, but the consistent open-market sales (code "S") indicate Frederika has been monetizing her equity position throughout the period, with no recent accumulation to offset the outflow.
AI-assisted summary